ADG116-1003
03 Nov 2020
Trial Summary
A Phase 1, Open-Label, Dose Escalation Study of ADG116 in Patients with Advanced/Metastatic Solid Tumors
Acronym:
ADG116-1003
ACTRN/NCT /ethics:
NCT04111445
Scientific title:
Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
Sponsor / Cooperative group:
Adagene Inc
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2020-09-23 |
| Anticipated End Date | 2021-07-01 |
Participating Hospitals
| Hospital | Icon Cancer Centre Adelaide |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| sue.yeend@icon.team | |
| Phone | 08 8292 2204 |
| Principal Investigator | Dr Francis Parnis |
| Recruitment Status | Recruiting |